Analysis of the Efficacy and Survival of Third-line Treatment 
in Advanced Non-small Cell Lung Cancer

Analysis of the Efficacy and Survival of Third-line Treatment 
in Advanced Non-small Cell Lung Cancer

Background and objective The appearance of highly effective and low toxic drugs enables an increasing number of advanced non-small cell lung cancer (NSCLC) patients to receive third-line therapy. No other standard choice for third-line therapy aside from erlotinib is possible. This study respectivel...

Full description

Bibliographic Details
Main Authors: Lan SHAO, Zhengbo SONG, Lin HU, Fajun XIE, Guangyuan LOU, Wei HONG, Cuiping GU, Dan HONG, Baochai LIN, Yiping ZHANG
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2012-06-01
Series:Chinese Journal of Lung Cancer
Subjects:
Lung neoplasms
Third-line treatment
Chemotherapy
Targeted therapy
Prognosis
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2012.06.08

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2012.06.08

Similar Items